Фелметатуг ведотин

Prop. INN (наименование, предложенное ВОЗ)

2924808-30-8

immunoglobulin G1-kappa, anti-[Homo sapiens VTCN1 (V-set domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4)], Homo sapiens monoclonal antibody, conjugated on an average of four cysteinyl residues to vedotin, comprising a cleavable linker and monomethylauristatin E (MMAE);
H-gamma1 heavy chain Homo sapiens (1-450) [VH (Homo sapiens IGHV4-39*01 (96.0%) -(IGHD) -IGHJ5*02 (93.8%), CDR-IMGT [10.7.12] (26-35.53-59.98-109)) (1-120) -Homo sapiens IGHG1*01 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-15*01 (96.8%) -IGKJ4*01 (91.7%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, glycoform alfa; substituted at the sulfur atoms of four l-cysteinyl residues on an average among 223, 229, 232, 214', 223'', 229'', 232'' and 214''' with a group consisting of (3RS)-1-(6-{[(2S)-1-{[(2S)-5-(carbamoylamino)-1-{4-[({[(2S)-1-{[(2S)-1-{[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl](methyl)carbamoyl}oxy)methyl]anilino}-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]amino}-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl (vedotin)

Поделиться этой страницей